Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology · Clear Cell Sarcoma of Soft Tissue

Biology and Diagnosis: Telling CCS Apart from Melanoma

At a Glance

Clear cell sarcoma (CCS) closely mimics melanoma under a microscope, but they require very different treatments. The only way to accurately distinguish CCS from melanoma is through molecular testing like FISH or NGS to check for the EWSR1-ATF1 genetic fusion, which is unique to CCS.

Clear Cell Sarcoma of Soft Tissue (CCS) is often called “the great mimicker” because it looks and acts so much like melanoma that even experienced doctors can find them difficult to tell apart without specialized testing [1][2]. While they share a similar “look,” they are driven by entirely different biological “engines.”

Why the Confusion? Shared Features

The reason for the historical name “melanoma of soft parts” is biological. Both CCS and melanoma arise from cells that have undergone melanocytic differentiation—meaning they have “learned” how to act like pigment-producing cells [1][3].

Because of this, both tumors share several key features:

  • Melanin Production: Both can produce the dark pigment melanin, which can sometimes make the tumor appear dark or pigmented [1][2].
  • Staining Markers: In a lab, both will typically test “positive” for specific proteins used to identify melanoma, such as S100, HMB45, and Melan-A [1][3].
  • Aggressive Nature: Both are high-grade malignancies (fast-growing, aggressive cells) with a high potential to spread to other parts of the body [4][5].

The Biological “Fingerprint”: The t(12;22) Translocation

Despite these similarities, the underlying cause of CCS is unique. CCS is a translocation-associated sarcoma [6]. A translocation occurs when a piece of one chromosome breaks off and attaches to another, creating a new, abnormal “fusion gene” that acts as a permanent “on” switch for cancer growth [7].

  • The Blueprint: In about 90% of CCS cases, a piece of chromosome 22 swaps places with a piece of chromosome 12, written as t(12;22)(q13;q12) [6][8].
  • The Fusion: This swap fuses two genes together: EWSR1 and ATF1 (or more rarely, EWSR1 and CREB1) [9][8].
  • The Result: This new EWSR1-ATF1 fusion protein tells the cell to grow and divide uncontrollably [7].

Crucially, this specific genetic swap is never found in cutaneous melanoma [10][11]. Melanoma is typically driven by different mutations, such as the BRAF or NRAS mutations [10].

Why Molecular Testing is Critical

Because the tumors look so similar under a microscope, molecular testing is the only way to be 100% certain of the diagnosis [12][13]. This is usually done through two main methods:

  1. FISH (Fluorescence In Situ Hybridization): A test that uses fluorescent probes to look for the break in the EWSR1 gene [12][14].
  2. NGS (Next-Generation Sequencing): A more detailed test that can read the exact genetic code to identify the specific fusion partner (like ATF1 or CREB1) [15].

A Critical Warning: If your local doctor suspects melanoma but the tumor was found deep under the skin, it is strongly advised to pause or question starting melanoma-specific systemic treatments until molecular testing (EWSR1 fusion) definitively confirms the diagnosis [12][16].

The Impact of a Misdiagnosis

Getting the diagnosis right is not just a matter of semantics; it fundamentally changes the treatment path [12][16].

Feature Clear Cell Sarcoma (CCS) Cutaneous Melanoma
Origin Deep soft tissue (tendons/fascia) [17] Skin surface (epidermis) [12]
Genetic Driver EWSR1-ATF1 fusion [6] BRAF or NRAS mutations [10]
Standard Treatment Aggressive surgery is primary [18] Surgery, Immunotherapy, or Targeted Therapy
Chemotherapy Often resistant to standard chemo [19] Generally not used as first-line

If a patient with CCS is misdiagnosed with “metastatic melanoma,” they might be given melanoma-specific drugs (like BRAF inhibitors) that are ineffective against their sarcoma [1][19]. However, this does not mean all melanoma treatments are useless for CCS; for example, certain immunotherapies (like PD-1 inhibitors) are actually being actively studied and showing potential in CCS clinical trials [20][21]. For these reasons, seeing a sarcoma specialist and confirming the diagnosis with molecular testing is the most important first step in care [19][13].

Next, you can learn how to check these tests yourself in Auditing Your Pathology Report. Or return to the Home Page.

Common questions in this guide

Why is clear cell sarcoma sometimes called melanoma of soft parts?
Clear cell sarcoma shares many biological features with melanoma, including the ability to produce melanin pigment and test positive for the same protein markers. Because they look so similar under a microscope, it was historically referred to as melanoma of soft parts before its unique genetics were discovered.
How do doctors confirm a clear cell sarcoma diagnosis over melanoma?
The only way to be completely certain is through specialized molecular testing like FISH or Next-Generation Sequencing (NGS). These tests look for the EWSR1-ATF1 or EWSR1-CREB1 fusion genes, which are found in clear cell sarcoma but never in cutaneous melanoma.
What happens if clear cell sarcoma is misdiagnosed as melanoma?
A misdiagnosis can lead to incorrect treatment, as clear cell sarcoma does not respond to standard melanoma targeted therapies like BRAF inhibitors. It is highly recommended to pause melanoma-specific systemic treatments until molecular testing confirms the exact diagnosis.
What is the t(12;22) translocation in clear cell sarcoma?
A translocation is a genetic swap where a piece of one chromosome breaks off and attaches to another. In most clear cell sarcoma cases, a piece of chromosome 12 swaps with chromosome 22, fusing the EWSR1 and ATF1 genes together to drive the cancer's growth.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my diagnosis confirmed using molecular testing like FISH or Next-Generation Sequencing (NGS)?
  2. 2.Did the pathology report show the presence of the t(12;22) translocation or the EWSR1-ATF1 fusion?
  3. 3.Were there any features, such as an epidermal 'in situ' component, that might point toward melanoma instead of CCS?
  4. 4.If this were melanoma, how would the treatment plan change compared to the plan for CCS?
  5. 5.Can you explain how the specific fusion gene found (like EWSR1-ATF1 versus EWSR1-CREB1) affects my prognosis or treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Clear cell sarcoma-A review.

    Ibrahim RM, Steenstrup Jensen S, Juel J

    Journal of orthopaedics 2018; (15(4)):963-966 doi:10.1016/j.jor.2018.08.039.

    PMID: 30210202
  2. 2

    Clear cell sarcoma of soft tissue in right parapharyngeal region: report of a rare case.

    Fan C, Yu J, Yang L, et al.

    International journal of clinical and experimental pathology 2015; (8(9)):10935-40.

    PMID: 26617810
  3. 3

    [Soft tissue clear cell sarcoma. A report of three cases].

    Bonatskaya AA, Minaeva AE, Vinogradov II

    Arkhiv patologii 2021; (83(3)):35-39 doi:10.17116/patol20218303135.

    PMID: 34041894
  4. 4

    Metastatic clear cell sarcoma of the pancreas: An overview.

    Ait Addi R

    World journal of clinical cases 2024; (12(29)):6262-6265 doi:10.12998/wjcc.v12.i29.6262.

    PMID: 39417060
  5. 5

    Trends of lymph node sampling and metastasis in pediatric and young adult patients with clear cell, epithelioid, and synovial sarcomas.

    Weller JH, Westermann C, Patel P, et al.

    Pediatric blood & cancer 2022; (69(6)):e29455 doi:10.1002/pbc.29455.

    PMID: 35466567
  6. 6

    Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.

    Nakai T, Imura Y, Tamiya H, et al.

    Cancer medicine 2017; (6(9)):2121-2130 doi:10.1002/cam4.1130.

    PMID: 28745431
  7. 7

    Protein arginine methyltransferase 5 is essential for oncogene product EWSR1-ATF1-mediated gene transcription in clear cell sarcoma.

    Li BX, David LL, Davis LE, Xiao X

    The Journal of biological chemistry 2022; (298(10)):102434 doi:10.1016/j.jbc.2022.102434.

    PMID: 36041632
  8. 8

    Superficial Clear Cell Sarcoma (Melanoma of Soft Parts) of the Large toe in an 80-Year-Old Female With a Rare Cytogenetic Translocation.

    Zambrano R, Moesch J, Davis ER, et al.

    Cureus 2020; (12(11)):e11719 doi:10.7759/cureus.11719.

    PMID: 33391950
  9. 9

    A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin.

    Galera M, Álvarez R, Arregui M, et al.

    Case reports in oncology 2023; (16(1)):1542-1550 doi:10.1159/000534935.

    PMID: 38074516
  10. 10

    Metastatic clear cell sarcoma of the pancreas: A sporadic cancer.

    Gebbia V, Carnaghi C

    World journal of clinical cases 2024; (12(18)):3291-3294 doi:10.12998/wjcc.v12.i18.3291.

    PMID: 38983428
  11. 11

    Brain metastasis from gastrointestinal clear cell sarcoma.

    Guraya SS, Prayson RA

    Clinical neuropathology 2017; (36 (2017)(1)):41-45 doi:10.5414/NP300965.

    PMID: 27719746
  12. 12

    Primary Clear Cell Sarcoma of the Dermis Mimicking Malignant Melanoma.

    Obiorah IE, Brenholz P, Özdemirli M

    Balkan medical journal 2018; (35(2)):203-207 doi:10.4274/balkanmedj.2017.0796.

    PMID: 29072181
  13. 13

    Clear-Cell Sarcoma With an Unusual Presentation Mimicking Metastatic Melanoma.

    Tahiri Elousrouti L, Hammas N, Elmernissi FZ, et al.

    Cureus 2022; (14(11)):e32010 doi:10.7759/cureus.32010.

    PMID: 36589177
  14. 14

    Clear Cell Sarcoma (CCS) of the Soft Tissue: An Update Narrative Review with Emphasis on the Utility of PRAME in Differential Diagnosis.

    Cazzato G, Piscazzi F, Filosa A, et al.

    Journal of clinical medicine 2025; (14(4)) doi:10.3390/jcm14041233.

    PMID: 40004764
  15. 15

    Compound clear cell sarcoma with EWSR1::CREM fusion.

    Li P, Busam K

    Journal of cutaneous pathology 2023; (50(12)):1065-1069 doi:10.1111/cup.14390.

    PMID: 36640048
  16. 16

    Cutaneous Melanocytic Tumor With CRTC1::TRIM11 Translocation : An Emerging Entity Analyzed in a Series of 41 Cases.

    Hanna J, Ko JS, Billings SD, et al.

    The American journal of surgical pathology 2022; (46(11)):1457-1466 doi:10.1097/PAS.0000000000001952.

    PMID: 35993578
  17. 17

    Morphology quiz: Cytology of a palmar swelling with axillary lymphadenopathy.

    Gupta P, Rajwanshi A

    Cytopathology : official journal of the British Society for Clinical Cytology 2018; (29(6)):592-594 doi:10.1111/cyt.12603.

    PMID: 29923360
  18. 18

    Factors associated with survival in patients with clear cell sarcoma.

    Fujiwara T, Kunisada T, Nakata E, et al.

    The bone & joint journal 2023; (105-B(11)):1216-1225 doi:10.1302/0301-620X.105B11.BJJ-2022-0743.R3.

    PMID: 37907082
  19. 19

    Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network.

    Smrke A, Frezza AM, Giani C, et al.

    ESMO open 2022; (7(3)):100522 doi:10.1016/j.esmoop.2022.100522.

    PMID: 35717681
  20. 20

    Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy.

    Li S, Sun Q, Bai R, et al.

    BMC cancer 2024; (24(1)):1028 doi:10.1186/s12885-024-12810-9.

    PMID: 39164643
  21. 21

    Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy.

    Sidlik Muskatel R, Pillar N, Godefroy J, et al.

    Frontiers in pediatrics 2022; (10()):940927 doi:10.3389/fped.2022.940927.

    PMID: 36275056

This page explains the biological differences between clear cell sarcoma and melanoma for educational purposes. Only a specialized sarcoma pathologist can definitively diagnose your specific tumor based on molecular testing.

Get notified when new evidence is published on Melanoma of soft tissue.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.